



Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Announcement of Interest to Receive Independent Medical Education (IME) Grant Applications

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is committed to supporting innovative, high quality, independent medical education for healthcare professionals that helps address unmet medical needs, maintains clinical excellence, and aims to improve patient health outcomes in BIPI's therapeutic areas of interest.

The intent of this Request for Proposals (RFP) announcement is to notify experienced and eligible medical education providers that BIPI is interested in receiving applications for IME activities pertinent to Metabolism and aligned to the specifications outlined below.

Such IME must be based on identified educational needs of healthcare provider-learners, be evidence-based in the aim to improve the care of patients, and may or may not offer continuing education (CE) credit. Importantly, BIPI-supported IME will adhere to relevant regulatory guidance and industry standards.

Grant applications must be submitted online at www.bipigrants.com and once received, BIPI will carefully consider each request with a goal to provide a decision less than 60 days from receipt. The outcome of each review may result in full or partial funding of the requested amount, or in a denial decision.

Unless otherwise noted on www.bipigrants.com, during the period of this RFP and throughout the year, BIPI will also accept requests from eligible organizations that are not in response to an RFP. Should those grant applications be received during the time of this RFP and align with the parameters outlined in this announcement, BIPI will review those applications and evaluate them according to the same quality and eligibility standards.

If you have questions about the RFP application process, please send an email to the Boehringer Ingelheim Pharmaceuticals Medical Education Professional at manita.singh@boehringer-ingelheim.com

RFP (Request for Proposals) Posting Date	July 24, 2026
RFP Submission Deadline	Accepted on an ONGOING basis until August 24, 2026 . Review is prioritized based on date of receipt, program requirements and available budget. You will submit via our grants portal – Lectrona .
Therapeutic Area	Metabolic (Obesity + Liver Health)
Educational Focus (Educational activities should address one or more of the following educational gaps):	1. Pathophysiology, Prevalence, Burden of Disease: a. Increase clinician knowledge of current evidence regarding interconnected biological pathways driving metabolic dysfunction, including novel mechanisms that influence body weight, liver health, body composition, the role of visceral adiposity on outcomes and cardiovascular risk for a broader view of obesity in overall metabolic health. b. Increase clinician knowledge of prevalence, morbidity, mortality, signs, and symptoms of obesity with weight related complications. 2. Screening, Risk Stratification, and Diagnosis: a. Increase clinician knowledge of the role of the liver in metabolic health for people living with obesity including but not limited to screening and diagnosis of metabolic conditions. b. Increase clinician competence in standardized diagnostic approaches, guideline directed medical therapy and routine care pathways/referral pathways. 3. Clinical Management: a. Increase clinician knowledge of evolving pathophysiologic frameworks that link metabolic dysfunction, obesity, and liver disease, and the implications for future integrated management approaches (e.g. glucagon/GLP-1).

Submission requirements are posted at <http://www.bipigrants.com>

	b. Increase clinician competence and confidence in anticipating the future therapeutic landscape for obesity and MASLD/MASH, including emerging multi-targeted strategies (e.g. glucagon/GLP-1) that address the interconnected drivers of cardiometabolic and hepatic health.
Audience/Learners	Educational activities should address the needs of: Endocrinology (MD, DO, NP, PA), Internal Medicine/Family Practice (MD, DO, NP, PA), Hepatology (MD, DO, NP, PA), Pharmacy Please explicitly state the target HCP learner for which the proposed program is intended and how the proposed program addresses the clinical gaps specific to the target HCP learner's clinical practice.
Educational Format(s)	Live/Virtual educational activities at the national level (e.g. AASLD, AHA) including case-based training programs, community building and collaborative cross disciplinary learning environments, satellite symposia and online activities.
Available Support	Proposal requests should not exceed \$250,000 Please note that BIPi encourages submission of grant applications with multiple sources of funding support.
Selection Criteria	Applications will be evaluated based upon: - Adherence to BIPi's IME Proposal Guidelines - Ability to meet all requirements in submission - Requestor's knowledge of and experience within the therapeutic area and disease state - Well defined and researched gap analysis/needs assessment that specifies the current practice gap of identified learners within the educational focus indicated - Education focused on supporting excellence in patient care - Linkage of educational needs to practical, and measurable learning objectives - Incorporation of adult learning principles and instructional design method, interaction, and innovation in the educational format that reflect the preferred learning styles of the target audience - Outcomes measures that are in alignment with learning objectives and educational format, utilizing best practices in assessment methods - Audience generation methods that are specific to the activity and target audience - Rigor of mechanisms in place to validate content and mitigate identified relevant financial relationships, including review and revision of content as necessary to ensure a balanced view of therapeutic options and elimination of commercial bias - Compliance with guidelines and regulations related to CME/CE or other local governance related to medical education, as applicable - Fiscal responsibility and fair market value
Outcomes Measures	Expected Moore's Level 4 (objective) outcomes. Moore DE Jr, Green JS, Gallis HA. <i>Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities</i> <u>Contin Educ Health Prof.</u> 2009 Winter; 29 (1):1-15.
References	- Needs Assessment on File, December 2025. - Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. <i>Hepatology.</i> 2026;83(5):1326–1340. - American Heart Association. <i>Cardiovascular–Kidney–Metabolic Health Implementation Guide.</i> March 2026. - Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. <i>Nat Med.</i> 2026;32(6):1–24. - le Roux CW, Wharton S, Startseva E, et al. Survodutide, a once-weekly dual glucagon/GLP-1 receptor agonist, delivered significant weight loss and broad metabolic health benefits in adults. <i>N Engl J Med.</i> 2026. Published online June 7, 2026. doi:10.1056/NEJMoa2600166.

BIPI Standards for IME Applications:

1. This RFP does not commit BIPI to award a grant of any size nor to pay any costs incurred in the preparation of a response to this request. BIPI reserves the right to deny any applications and to not review applications it deems incomplete.
2. BIPI further reserves the right to request and to receive additional information and clarification relating to the submission; such a request would be provided by BIPI via e-mail.
3. All communications about the RFP must come exclusively to the BIPI Medical Education and Research Grants Office. Failure to comply may disqualify applicants. Applications received after the submission date or through other channels will not be considered.
4. BIPI adheres to both Federal and State Transparency Reporting Regulations and as such will report transfers of value from education grants provided to Health Care Providers and medical, scientific, and patient organizations.
5. Grant funding shall be paid directly only to the entity that is specified in the grant application as "applicant". BIPI will not make any payments to any individuals or co-sponsors of the educational program. No grant has been awarded until a formal grant agreement has been fully executed between BIPI and the applicant.
6. All applications must have comprehensive and itemized budgets.
7. Grantees must reconcile expenses and provide an outcomes report upon completion of the BIPI-supported educational program.